瑞舒伐他汀对冠心病患者血清CTRP9及ghrelin水平的影响

The effects of Rosuvastatin on serum CTRP 9 and ghrelin levels in patients with coronary artery disease

目的探讨冠心病患者血清脂肪细胞因子C1 q/肿瘤坏死因子相关蛋白9(C1 q/TNF—related proteiN,CTRP 9)及生长素释放肽(glrelin)水平与疾病的关系,并观察使用瑞舒伐他汀治疗后两者水平的变化。方法选择120例冠心病患者和80名正常对照者,检测2组血清CTRP9及ghrelin水平。120例冠心病患者进一步随机分为常规治疗组和瑞舒服他汀组,后者在常规治疗基础上,加服瑞舒伐他汀10 mg/d,治疗4周后观察2患者血清以CTRP9及glrelin水平。结果与正常对照组相比,冠心病患者血清CTRP9及glrelin水平显著降低(P<0.05),Logistic回归分析表明,血清CTRP9及glrelin是冠心病的独立保护因子。治疗4周后,瑞舒伐他汀组血清CTRP9及glrelin水平较治疗前显著升高(P<0.05),而常规治疗组其血清水平无明显变化。结论冠心病患者血清CTRP9及glrelin水平明显降低,二者是冠心病独立的保护因素,瑞舒伐他汀可升高冠心病血清CTRP9及glrelin水平。

Objective To investigate the association of serum levels of C1 q/TNF-related protein (CTRP 9) and ghrelin with coronary artery disease, and observe the effects of Rosuvastain on serum CTRP 9 and ghrelin. Method Serum levels of CTRP 9 and ghrelin in 120 patients with coronary artery disease and 80 healthy controls were measured. Then 120 patients were randomly divided into control group and Rosuvastatin group. Patients in both groups were given regular treatment. In addition, patients in Rosuvastatin group were treated with Rosuvastatin (10 mg/d) for 4 weeks. Serum levels of CTRP 9 and ghrelin in the two groups were examined before and after treatment. Results Serum levels of CTRP 9 and ghrelin were significantly decreased in patients with coronary artery disease compared with those in controls (P<0.05). Logistic regression analysis revealed that reduced levels of serum CTRP 9 and ghrelin were independent risk factors of coronary artery disease. After 4 weeks of treatment with Rosuvastatin, serum levels of CTRP 9 and ghrelin were significantly increased (P<0.05). However, no significant differences of serum CTRP 9 and ghrelin were found in control group before and after regular treatment (P>0.05). Conclusion Serum levels of CTRP 9 and ghrelin are significantly decreased in patients with coronary artery disease and they are independent protective factors of coronary artery disease. Rosuvastatin may improve the levels of CTRP 9 and ghrelin for patients with coronary artery disease.